News

The consultant in the Department of Neurology at Mayo Clinic discussed the mounting number of unmet needs for patients with Parkinson disease.

A majority of patients across all 3 cohorts maintained or improved their motor function shown by changes from baseline in Revised Hammersmith Scale scores.

A case report showed 1 patient in the vaccine arm developed Guillain-Barré syndrome, though 1 in the placebo arm also developed the syndrome, implying coincidence rather than causation.

The senior director of patient management, care, and rehabilitation research at the National MS Society discussed the lack of studies on progressive MS compared to RRMS.

Researchers found significant differences between clinically relevant areas in participants with progressive MS, relapsing MS, and healthy controls.

Overall, 91% of participants in the pooled bimagrumab group and 89.1% in the placebo group had at least 1 or more treatment-emergent adverse event.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine provided plans of action to reduce racial and ethnic disparities in stroke.

The consultant in the department of neurology at Mayo Clinic detailed a number of topics surrounding Parkinson Disease Awareness Month, including the progress made in the last 2 decades.

Stephanie Blandford, MSc, a PhD candidate at Memorial University of Newfoundland, discussed some advantages of using IL-1RA over NfL in predicting disability in multiple sclerosis.

The PhD candidate at the Barts MS Center in London discussed the upcoming Chariot MS study as well as further research she would like to conduct in personalized cladribine dosing.

Researchers studied concentrations of recombinant tissue plasminogen activator locally and systemically in patients with IS.

Patients with a history of abuse reported a higher average or median questionnaire scores that focused on anxiety, depression, photophobia, hyperacusis, ictal allodynia, and interictal allodynia.

Alise Carlson, MD, a resident at Cleveland Clinic, provided insight on how raising awareness for genetic leukodystrophies may ultimately improve misdiagnosis rates.

Alzheimer disease-related neurodegeneration was correlated only with the thickness of the ganglion cell-inner plexiform layer.

The chief medical officer of Biohaven Pharmaceuticals discussed the recently initiated phase 2/3 clinical trial of zavegepant for the prevention of migraine.

Researchers found a 70% infarct resolution and 90% motor recovery in mice injected with the EFF-nanotransfected cells.

The director and founder of the Sleep Centers of Middle Tennessee discussed his team’s efforts to further patient understanding of obstructive sleep apnea.

There were no significant treatment group differences for measures of Alzheimer disease regional atrophy, cerebral blood flow, or mean fractional anisotropy.

Episode 8 of the AUPN Leadership Minute features Rohit Das, MD, of University of Texas Southwestern Medical Center at Dallas; and Robert M. Pascuzzi, MD, of Indiana University School of Medicine. [WATCH TIME: 4 minutes]

The FDA cited a lack of statistical significance in some of the subgroups of dementia, and insufficient numbers of patients with certain less common dementia subtypes as lack of substantial evidence of effectiveness to support approval.

The consultant in the department of neurology at Mayo Clinic discussed Parkinson Disease Awareness Month and the benefits behind social initiatives that raise awareness.

Here's what is coming soon to NeurologyLive.

The duo from Montefiore Medical Center discussed aspects of their recently published recommendations on neonatal seizure diagnosis that need further examining.

The randomized, double-blind, placebo-controlled trial will enroll approximately 2900 people with migraine and will evaluate the efficacy and safety of 100- and 200-mg zavegepant.

The professor of clinical neurology at University of Miami and MT2020+ chair, and president of Medtronic's Neurovascular Business discussed the effort to improve global accessibility of mechanical thrombectomy.

Researchers from Jefferson Health developed predictive models to assess risk of kidney injury and stroke after surgery.

Researchers found improvements in SIB and NPI score between high-dose and placebo groups.

Neurology News Network for the week ending April 3, 2021.

Researchers on the FDA’s advisory committee conducted a review of the studies and evidence ahead of the treatment’s PDUFA date on June 7, 2021.

A series of video modules aims to address the unique challenges faced by nursing professionals caring for patients with MS in rural areas.